Analyst Ratings For Spark Therapeutics (NASDAQ:ONCE)
Today, Credit Suisse Group reiterated its Outperform rating on Spark Therapeutics (NASDAQ:ONCE) with a price target of $75.00.
Some recent analyst ratings include
- 3/8/2018-Credit Suisse Group Reiterated Rating of Outperform.
- 2/21/2018-Sanford C. Bernstein Reiterated Rating of Buy.
- 2/21/2018-Stifel Nicolaus Reiterated Rating of Buy .
- 2/21/2018-Mizuho Reiterated Rating of Buy.
Recent Insider Trading Activity For Spark Therapeutics (NASDAQ:ONCE)
Spark Therapeutics (NASDAQ:ONCE) has insider ownership of 7.30% and institutional ownership of 99.87%.
- On 12/11/2017 John Furey, COO, sold 18 with an average share price of $46.33 per share and the total transaction amounting to $833.94.
- On 12/8/2017 John Furey, COO, bought 18 with an average share price of $73.48 per share and the total transaction amounting to $1,322.64.
- On 11/28/2017 Katherine A High, Insider, sold 5,000 with an average share price of $71.32 per share and the total transaction amounting to $356,600.00.
- On 11/16/2017 Stephen W Webster, CFO, sold 10,000 with an average share price of $70.14 per share and the total transaction amounting to $701,400.00.
- On 11/13/2017 Barge Joseph La, Insider, sold 5,500 with an average share price of $71.44 per share and the total transaction amounting to $392,920.00.
- On 11/13/2017 Jeffrey D Marrazzo, CEO, sold 20,000 with an average share price of $71.54 per share and the total transaction amounting to $1,430,800.00.
- On 11/9/2017 Barge Joseph La, Insider, sold 3,309 with an average share price of $71.31 per share and the total transaction amounting to $235,964.79.
Recent Trading Activity for Spark Therapeutics (NASDAQ:ONCE)
Shares of Spark Therapeutics closed the previous trading session at 64.13 down -0.37 0.57% with 63.59000015258789 shares trading hands.